Abstract
Early diagnosis of TB is essential for community health and infection control, as well as for starting appropriate therapy for patients. Early detection of MDR is essential for the same reasons, plus the fact that currently a very high percentage of MDR patients die, especially in developing countries. Both genotypic and phenotypic methods allowing assessment of MDR tuberculosis on the bacilli isolated from fluids of infected patients are available, but these tests are lengthy (6-16 weeks) and require infected body fluids, which are not always easily assessable. Patients presenting pulmonary TB can also be culture-negative.
Diagnosis of active disease in a pulmonary tuberculoma has long been problematic because the non-specific character of the disease, its changing manifestations and the slow growth of the organisms make its isolation a long and time-consuming process. Determination of pulmonary tuberculoma activity may be mandatory for optimal treatment strategy, therefore imaging techniques may be helpful in early detection.
The aim of this review is to assess the role of Positron Emission Tomography (PET) imaging in the diagnosis and therapy management of TB. Although studies and data on the potential role of FDG PET in the diagnosis of tuberculosis are limited, a literature search revealed some interesting studies on this subject. Most of the studies described indicate that PET imaging, especially FDG PET as diagnostic tool, could be a noninvasive method that gives additional information about the disease status, enabling improved therapeutic management of pulmonary mycobacterial infection. Furthermore, several studies provide evidence that PET imaging could be useful in tuberculostatic therapy evaluation.
Keywords: Positron emission tomography, tuberculosis, diagnosis, FDG, biopsy, sterilization, lymph node, radiopharmaceuticals, sputum, extrapulmonary tuberculosis
Current Pharmaceutical Design
Title: Positron Emission Tomography in the Diagnosis and Treatment Management of Tuberculosis
Volume: 17 Issue: 27
Author(s): J. G.W. Kosterink
Affiliation:
Keywords: Positron emission tomography, tuberculosis, diagnosis, FDG, biopsy, sterilization, lymph node, radiopharmaceuticals, sputum, extrapulmonary tuberculosis
Abstract: Early diagnosis of TB is essential for community health and infection control, as well as for starting appropriate therapy for patients. Early detection of MDR is essential for the same reasons, plus the fact that currently a very high percentage of MDR patients die, especially in developing countries. Both genotypic and phenotypic methods allowing assessment of MDR tuberculosis on the bacilli isolated from fluids of infected patients are available, but these tests are lengthy (6-16 weeks) and require infected body fluids, which are not always easily assessable. Patients presenting pulmonary TB can also be culture-negative.
Diagnosis of active disease in a pulmonary tuberculoma has long been problematic because the non-specific character of the disease, its changing manifestations and the slow growth of the organisms make its isolation a long and time-consuming process. Determination of pulmonary tuberculoma activity may be mandatory for optimal treatment strategy, therefore imaging techniques may be helpful in early detection.
The aim of this review is to assess the role of Positron Emission Tomography (PET) imaging in the diagnosis and therapy management of TB. Although studies and data on the potential role of FDG PET in the diagnosis of tuberculosis are limited, a literature search revealed some interesting studies on this subject. Most of the studies described indicate that PET imaging, especially FDG PET as diagnostic tool, could be a noninvasive method that gives additional information about the disease status, enabling improved therapeutic management of pulmonary mycobacterial infection. Furthermore, several studies provide evidence that PET imaging could be useful in tuberculostatic therapy evaluation.
Export Options
About this article
Cite this article as:
G.W. Kosterink J., Positron Emission Tomography in the Diagnosis and Treatment Management of Tuberculosis, Current Pharmaceutical Design 2011; 17 (27) . https://dx.doi.org/10.2174/138161211797470183
DOI https://dx.doi.org/10.2174/138161211797470183 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rapid and Convenient CuCl2 Catalysed Microwave-Assisted Synthesis of Novel Spiro [indoline-3,4'-quinoline] Derivatives
Current Microwave Chemistry Structure and Mechanism of Arylamine N-Acetyltransferases
Current Topics in Medicinal Chemistry Biological Therapies of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Design, Synthesis and Biological Evaluation of Carbazole Derivatives as Antitubercular and Antibacterial Agents
Current Bioactive Compounds Rationalizing the Study of Plants for the Treatment of Oral Pain
Current Chemical Biology New Approaches to Tuberculosis - Novel Drugs Based on Drug Targets Related to Toll-Like Receptors in Macrophages
Current Pharmaceutical Design Vitamins B1, B2, B3 and B9 – Occurrence, Biosynthesis Pathways and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry 1, 4-Dihydropyridines: A Class of Pharmacologically Important Molecules
Mini-Reviews in Medicinal Chemistry Inhibitors of Types I and II Dehydroquinase
Mini-Reviews in Medicinal Chemistry Targeted Drug Delivery in Brain Tumors-nanochemistry Applications and Advances
Current Topics in Medicinal Chemistry Anti-Inflammatory Agents from Plants: Progress and Potential
Current Medicinal Chemistry Natural Products Containing Olefinic Bond: Important Substrates for Semi-synthetic Modification Towards Value Addition
Current Organic Chemistry Anti-Tubercular and Anti-Inflammatory Activities of Azetidin-2-One Derivatives and Their Effects on the Activity of Phospholipase A2
Medicinal Chemistry Applications of Docking and Molecular Dynamic Studies on the Search for New Drugs Against the Biological Warfare Agents Bacillus anthracis and Yersinia pestis
Current Computer-Aided Drug Design From Mice to Macaques – Animal Models of HIV Nervous System Disease
Current HIV Research Clinical Development of Cationic Antimicrobial Peptides: From Natural to Novel Antibiotics
Current Drug Targets - Infectious Disorders Nanoparticles for Cancer Targeting: Current and Future Directions
Current Drug Delivery Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Current Cancer Drug Targets A Review of the Computational Methods for Identifying the Over- Annotated Genes and Missing Genes in Microbial Genomes
Current Bioinformatics Synthesis and Anti-Mycobacterial Activity of N-[(E)-(Disubstituted- Phenyl)Methylidene]Isonicotino-Hydrazide Derivatives
Letters in Drug Design & Discovery